Skip to main content
VERICI DX PLC logo

VERICI DX PLC — Investor Relations & Filings

Ticker · VRCI ISIN · GB00BM8HZD43 LEI · 213800FI5WE4FVQ3G645 IL Real estate activities
Open in API
Filings indexed 192 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country GB United Kingdom
Listing IL VRCI

About VERICI DX PLC

https://www.vericidx.com/

Verici Dx is an immuno-diagnostics company developing and commercializing a suite of proprietary tests for the kidney transplant market. The company's platform utilizes artificial intelligence-assisted transcriptomic analysis of RNA signatures to provide data-driven insights to clinicians. These tests are designed to decipher the body's immune response and other biological signals, enabling personalized risk assessment for organ injury, rejection, and graft failure. The goal is to assist clinicians in medical management throughout the transplant process, from pre-transplant to late-stage care, ultimately aiming to improve patient outcomes and long-term graft survival.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Regulatory Filings
2026-06-02 English
Study validating economic advantages of PTRA test
Regulatory Filings
2026-06-02 English
AMA grants additional CPT® Code for ProtegaTM
Regulatory Filings
2026-06-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 95% confidence The document is a TR-1 Standard form notification of major holdings under the UK’s Disclosure and Transparency Rules (DTR5), indicating a shareholding threshold being crossed (7.817838% by UBS Group AG/UBS AG). It is a regulatory announcement of a change in significant share ownership levels. This matches the “Major Shareholding Notification” category (Code: MRQ).
2026-05-27 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is a TR-1 “Standard form for notification of major holdings,” detailing the crossing of a shareholding threshold, reporting voting rights percentages, dates of threshold crossing and notification, and issuer/holder details. This matches the definition of a Major Shareholding Notification (Code: MRQ).
2026-05-22 English
Clinical study validating PTRA test published
Regulatory Filings Classification · 80% confidence The document is a press release distributed via the London Stock Exchange’s RNS service announcing the publication of a peer-reviewed clinical study by Verici Dx. It does not contain financial statements, voting results, management changes, M&A details, earnings data, or substantive report content but is a general regulatory news announcement. Under the filing definitions, this best fits the fallback category “Regulatory Filings” (RNS).
2026-05-19 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.